Intensity Therapeutics, Inc. (INTS)

Intensity Therapeutics will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$4.00 - $5.00
Shares Offered
Deal Size
Chart not available yet
Data will show when the stock starts trading.
Market Cap 80.93M
Revenue (ttm) n/a
Net Income (ttm) -7.13M
Shares Out 17.99M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About INTS

Intensity Therapeutics, Inc. is a clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform. Our platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Amphiphilic molecules have two distinct components: one part is soluble in water and ... [Read more...]

Industry Biotechnology
Founded 2012
CEO Lewis H. Bender
Employees 8
Stock Exchange NASDAQ
Ticker Symbol INTS
Full Company Profile

Financial Performance

Financial Statements


Intensity Therapeutics IPO Registration Document (S-1)

Intensity Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

11 months ago - SEC